Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392208 · ClinicalTrials.gov registry record · Phase 4
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
A Phase 4 study of End Stage Renal Disease and Stage 5 Chronic Kidney Disease, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02392208: Completed Phase 4 study of End Stage Renal Disease and Stage 5 Chronic Kidney Disease, sponsored by University of Michigan.
NCT02392208 is a Phase 4 study of End Stage Renal Disease and Stage 5 Chronic Kidney Disease that has completed, run by University of Michigan. The registered enrollment target is 8 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02392208, a Phase 4 study of End Stage Renal Disease and Stage 5 Chronic Kidney Disease, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Chronic Kidney Disease Stage 5 (CKD5) patients receiving maintenance hemodialysis are at an increased risk for developing bloodstream infections. Vancomycin is traditionally used as first-line therapy for treating these infections, but the emergence of less-susceptible bacterial strains necessitates the consideration of alternative antibiotic therapy. Telavancin is a new antibiotic that has broad-spectrum antimicrobial activity against gram-positive bacteria, including vancomycin-intermediate staphylococcus aureus. While dosing recommendations for telavancin are available for patients with normal kidney function, there are no published recommendations for CKD5 patients receiving hemodialysis. A pharmacokinetic study is needed to characterize the pharmacokinetic parameters of telavancin in these patients to determine the extent of drug removal by hemodialysis and to establish dosing recommendations for CKD5 patients on maintenance hemodialysis.
Primary Outcome
Peak concentration of telavancin
Conditions Studied
Interventions
- DRUG Telavancin
- PROCEDURE Pharmacokinetic Blood Sampling
Study Locations (1)
Michigan
- University of Michigan Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-03 |
| Phase | Phase 4 |
What the finished NCT02392208 record still lists
NCT02392208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Telavancin is the first listed.
NCT02392208 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02392208 about?
NCT02392208 is a clinical study titled "Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5". Chronic Kidney Disease Stage 5 (CKD5) patients receiving maintenance hemodialysis are at an increased risk for developing bloodstream infections. Vancomycin is traditionally used as first-line therapy for treating these infections, but the emergence of less-susceptible bacterial strains necessitates...
What is the current status of trial NCT02392208?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2015-07. Estimated completion is 2016-03.
What conditions does trial NCT02392208 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Stage 5 Chronic Kidney Disease.
What interventions are being tested in trial NCT02392208?
The interventions under investigation include: Telavancin (DRUG), Pharmacokinetic Blood Sampling (PROCEDURE).
Who is sponsoring clinical trial NCT02392208?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02392208 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02392208's enrollment target sits among peer trials
8 82nd of 86 higher than 4 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
-
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
COMPLETED · Phase 4
-
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
COMPLETED · Phase 4
-
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
COMPLETED · Phase 4
-
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia